Featured Oncology News
Peer-Spectives is a new podcast series that is moderated by our editor-in-chief Robert Figlin, MD, and
features select thought-leaders covering the latest clinical developments in a wide range of cancer settings.
Moderated by:
Steven Spielberg Family
Chair in Hematology-Oncology
Cedars-Sinai Medical Center
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care,
and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
FDA Action Alert: Exelixis and Immunomedics
Researchers Uncover Major Clue In Predicting Response To Immunotherapy
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
San Francisco, CA
San Francisco, CA
Amsterdam, The Netherlands
Santa Monica, CA
Washington, DC
Orlando, FL
Atlanta, GA
Orlando, FL
Geneva, Switzerland
Denver, CO
Chicago, IL
RAI Amsterdam, The Netherlands
Lugano, Switzerland
San Francisco, CA
Buenos Aires, Argentina
Orlando, FL
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Exelixis Announces U.S. FDA Approval of CABOMETYX® ...
January 15th 2019 by Howard S. Hochster, MD
Another TKI for HCC! We now have 3 agents with variable tolerability profiles. Good news for pati...
Read More
Researchers Uncover Major Clue In Predicting Respons...
January 14th 2019 by Tomasz M. Beer, MD, FACP
It is fascinating to see that greater complexity of cancer, typically associated with more aggressi...
Read More
Minister to ‘Talk To Novartis’ After Five-Fold C...
January 13th 2019 by
Outrageous.... There is urgent an need to regulate the drug prices and reign in the greed of the bi...
Read More
Prescription Drug Costs Driven By Manufacturer Price...
January 10th 2019 by William McGivney, PhD
ONLY Invested Over $100 Billion in R and D A quote in the summary ar...
Read More
Physician Burnout -- These Characters Are To Blame
January 10th 2019 by Tomasz M. Beer, MD, FACP
We must take burnout seriously if we are to retain a robust physician work force. I would offer on...
Read More
Merck Provides Update on KEYTRUDA® (pembrolizumab) ...
December 21st 2018 by H. Jack West, MD
This is an indication that, if approved, most lung cancer specialists won't be eager to support. Th...
Read More
OBR Green